drugset / Trial / NCT05322850
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
Phase 1/2
Suspended
40 enrolled
University of Florida
Florida Department of Health · collabOrca Biosystems, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a first in children prospective study of allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q). The study will assess safety and efficacy of Orca-Q in pediatric patients with hematologic malignancies.
Timeline
- Start
- 2022-08-16
- Primary completion
- 2026-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orca-Q | Cell therapy | — | Intravenous |